AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26406218 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser (n = 15)
Number of subjects: 45
Study 26406218 — intervention group
Group type: EXPERIMENTAL
Intervention: Taping applications (n = 15)
Number of subjects: 45
Study 26406218 — intervention group
Group type: COMPARATOR
Intervention: Placebo Laser (n = 15)
Number of subjects: 45
Study 26233647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 49
Study 26233647 — intervention group
Group type: EXPERIMENTAL
Intervention: New strict ECG criteria for CRT response
Number of subjects: 49
Study 26233647 — intervention group
Group type: EXPERIMENTAL
Intervention: RV-LV-IED measurement
Number of subjects: 49
Study 24119478 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncemented total hip endoprosthesis after Chiari pelvic osteotomy
Number of subjects: 75
Study 24119478 — intervention group
Group type: COMPARATOR
Intervention: Total hip arthroplasty due to degenerative hip dysplasia
Number of subjects: 75
Study 24119478 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between groups
Number of subjects: 75
Study 21076278 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine (ETR) 400 mg daily
Number of subjects: 58
Study 21076278 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz (EFV)
Number of subjects: 58
Study 21076278 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement of EFV with ETR
Number of subjects: 58
Study 21076278 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of sleep, depression, anxiety and stress scores
Number of subjects: 58
Study 18362380 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones (moxifloxacin, levofloxacin, gatifloxacin)
Number of subjects: 2133
Study 18362380 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroquinolones
Number of subjects: 2133
Study 16290928 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 0
Study 15204476 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education Programme
Number of subjects: 229
Study 15204476 — intervention group
Group type: COMPARATOR
Intervention: Individual Intervention Programme
Number of subjects: 229
Study 11257751 — intervention group
Group type: EXPERIMENTAL
Intervention: Local corticosteroid injections
Number of subjects: 30
Study 11257751 — intervention group
Group type: COMPARATOR
Intervention: Wrist splinting
Number of subjects: 30
Study 9262126 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (150 mg daily)
Number of subjects: 45
Study 9262126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 8517427 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 15
Study 8517427 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3326874 — intervention group
Group type: EXPERIMENTAL
Intervention: Chalcone Ro 09-0410
Number of subjects: 50
Study 3326874 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 28726492 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-specific computer training (NCT) using Nintendo Wii for improving functional performance
Number of subjects: 78
Study 28726492 — intervention group
Group type: COMPARATOR
Intervention: Cognition-specific computer training (CCT) using CoTras for improving cognitive function
Number of subjects: 78
Study 27208876 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (soda water)
Number of subjects: 83
Study 27208876 — intervention group
Group type: EXPERIMENTAL
Intervention: SDF solution
Number of subjects: 83
Study 27208876 — intervention group
Group type: EXPERIMENTAL
Intervention: SDF solution followed by potassium iodide (KI) solution
Number of subjects: 83
Study 24735806 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 10mg
Number of subjects: 301
Study 24735806 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitopertin 30mg
Number of subjects: 301
Study 24735806 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 15mg
Number of subjects: 301
Study 24735806 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 22534589 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (45-minute teaching session reviewing hospital bills and discussing cost reduction)
Number of subjects: 96
Study 19735754 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg/day vitamin D(3) supplementation
Number of subjects: 221
Study 19735754 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/day vitamin D(3) supplementation
Number of subjects: 221
Study 19735754 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (5 or 10 microg/day)
Number of subjects: 221
Study 19735754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 18446736 — intervention group
Group type: EXPERIMENTAL
Intervention: Cool dialysate (35 degrees C)
Number of subjects: 7
Study 18446736 — intervention group
Group type: COMPARATOR
Intervention: Warm dialysate (37 degrees C)
Number of subjects: 7
Study 15741544 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirazid (300 mg/day for three consecutive days)
Number of subjects: 1131
Study 15741544 — intervention group
Group type: COMPARATOR
Intervention: Praziquantel (single dose of 40 mg/kg)
Number of subjects: 1131
Study 12875093 — intervention group
Group type: EXPERIMENTAL
Intervention: Home enteral nutrition (HEN) with a mean of 1650 Kcal of enteral solution
Number of subjects: 92
Study 12875093 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous gastrostomy
Number of subjects: 92
Study 12875093 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric tube
Number of subjects: 92
Study 12875093 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical gastrostomy
Number of subjects: 92
Study 10215715 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask
Number of subjects: 26
Study 10215715 — intervention group
Group type: EXPERIMENTAL
Intervention: Combitube
Number of subjects: 26
Study 7762065 — intervention group
Group type: EXPERIMENTAL
Intervention: Enisoprost (EP) 100 mg p.o. t.i.d. for 12 weeks
Number of subjects: 81
Study 7762065 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 81
Study 7762065 — intervention group
Group type: EXPERIMENTAL
Intervention: Enisoprost (EP)
Number of subjects: 81
Study 7762065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 2685206 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program (Quit for Life)
Number of subjects: 44
Study 2685206 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients of experimental physicians
Number of subjects: 44
Study 30975478 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hip precautions (SHP)
Number of subjects: 313
Study 30975478 — intervention group
Group type: COMPARATOR
Intervention: No hip precautions (NHP)
Number of subjects: 313
Study 28110408 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with distraction osteogenesis (DO)
Number of subjects: 55
Study 28110408 — intervention group
Group type: COMPARATOR
Intervention: Extraction of lower premolars (Ex)
Number of subjects: 55
Study 28110408 — intervention group
Group type: COMPARATOR
Intervention: Nonex (without extractions)
Number of subjects: 55
Study 26150704 — intervention group
Group type: EXPERIMENTAL
Intervention: Left radial approach (LRA)
Number of subjects: 200
Study 26150704 — intervention group
Group type: COMPARATOR
Intervention: Right radial approach (RRA)
Number of subjects: 200
Study 23523240 — intervention group
Group type: EXPERIMENTAL
Intervention: R-ZES
Number of subjects: 400
Study 23523240 — intervention group
Group type: COMPARATOR
Intervention: PES
Number of subjects: 400
Study 21880792 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 1717
Study 21880792 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 1717
Study 19640733 — intervention group
Group type: COMPARATOR
Intervention: Recovery filter
Number of subjects: 241
Study 19640733 — intervention group
Group type: EXPERIMENTAL
Intervention: G2 filter
Number of subjects: 241
Study 17596694 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador therapy (mistletoe preparation)
Number of subjects: 187
Study 17596694 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Iscador therapy)
Number of subjects: 187
Study 15345106 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (n = 18) informed of the protective effect of beta-thalassemia trait against malaria and coronary heart disease
Number of subjects: 28
Study 15345106 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10) received the same information after the second interview
Number of subjects: 28
Study 11159657 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate antibiotics
Number of subjects: 315
Study 11159657 — intervention group
Group type: COMPARATOR
Intervention: Delayed antibiotics
Number of subjects: 315
Study 10093796 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraarticular injections of sodium hyaluronate (20 mg) plus steroid (20 mg triamcinolone acetonide) and physiotherapy
Number of subjects: 30
Study 10093796 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular injections of steroid (20 mg triamcinolone acetonide) alone and physiotherapy
Number of subjects: 30
Study 7820469 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping of the long saphenous vein (LSV)
Number of subjects: 89
Study 2945705 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% metronidazole in an emollient cream base
Number of subjects: 75
Study 2945705 — intervention group
Group type: COMPARATOR
Intervention: 250 mg oral tetracycline taken twice daily
Number of subjects: 75
Study 30052315 — intervention group
Group type: EXPERIMENTAL
Intervention: CRMRF (calorie-restricted diet with meal replacement and fish oil supplementation)
Number of subjects: 93
Study 30052315 — intervention group
Group type: COMPARATOR
Intervention: CRMR (calorie-restricted diet with meal replacement alone)
Number of subjects: 93
Study 27016729 — intervention group
Group type: EXPERIMENTAL
Intervention: First-generation antipsychotics (haloperidol and flupentixol)
Number of subjects: 0
Study 27016729 — intervention group
Group type: COMPARATOR
Intervention: Second-generation antipsychotics (olanzapine, aripiprazole and quetiapine)
Number of subjects: 0
Study 24393305 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone outcall intervention program
Number of subjects: 230
Study 24393305 — intervention group
Group type: COMPARATOR
Intervention: Minimal outcall / attention control service
Number of subjects: 230
Study 22307237 — intervention group
Group type: EXPERIMENTAL
Intervention: Periconceptional maternal micronutrient supplementation
Number of subjects: 0
Study 22307237 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20473735 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg once a day)
Number of subjects: 90
Study 20473735 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang Capsule (600 mg, twice a day) and Valsartan (80 mg once a day)
Number of subjects: 90
Study 20473735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 90
Study 20473735 — intervention group
Group type: COMPARATOR
Intervention: Xuezhikang Capsule and Valsartan vs Control group
Number of subjects: 90
Study 20473735 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang Capsule and Valsartan vs Valsartan group
Number of subjects: 90
Study 18678684 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered interpersonal psychotherapy (teletherapy group)
Number of subjects: 79
Study 18678684 — intervention group
Group type: COMPARATOR
Intervention: Usual care control condition
Number of subjects: 79
Study 18539223 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 1071
Study 18539223 — intervention group
Group type: COMPARATOR
Intervention: Conventional PCI
Number of subjects: 1071
Study 15470940 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based drug abuse prevention program
Number of subjects: 0
Study 15470940 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug prevention program)
Number of subjects: 0
Study 11226996 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (40 microg/kg)
Number of subjects: 90
Study 11226996 — intervention group
Group type: COMPARATOR
Intervention: Droperidol (50 microg/kg)
Number of subjects: 90
Study 11226996 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (0.25 mg/kg)
Number of subjects: 90
Study 9028087 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin 2 million KIU
Number of subjects: 21
Study 9028087 — intervention group
Group type: COMPARATOR
Intervention: Normal saline placebo (control)
Number of subjects: 21
Study 8471083 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.75 g/kg)
Number of subjects: 10
Study 2980546 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 20
Study 2980546 — intervention group
Group type: COMPARATOR
Intervention: meglumine-Ca-metrizoate
Number of subjects: 20
Study 31254675 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 199
Study 30159739 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee brace (12 weeks postoperative therapy)
Number of subjects: 63
Study 30159739 — intervention group
Group type: EXPERIMENTAL
Intervention: Wedge insoles (12 weeks postoperative therapy)
Number of subjects: 63
Study 30159739 — intervention group
Group type: COMPARATOR
Intervention: No specific postoperative therapy (control group)
Number of subjects: 63
Study 29049469 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone, 380 mg, administered intramuscularly every fourth week for 12 weeks
Number of subjects: 232
Study 29049469 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone, daily oral flexible dose 4 to 24 mg/d
Number of subjects: 232
Study 29049469 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone
Number of subjects: 232
Study 29049469 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine-naloxone
Number of subjects: 232
Study 26081066 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP concentrations in women who developed CVD (81 ng/l [50 to 147])
Number of subjects: 480
Study 26081066 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP in the highest quartile compared to the lowest quartile
Number of subjects: 480
Study 26081066 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP as a continuous variable
Number of subjects: 480
Study 26081066 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP per 1-SD change in Ln(NT‐proBNP) for cardiovascular death
Number of subjects: 480
Study 26081066 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP per 1-SD change in Ln(NT‐proBNP) for stroke
Number of subjects: 480
Study 26081066 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP per 1-SD change in Ln(NT‐proBNP) for myocardial infarction
Number of subjects: 480
Study 26081066 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP added to traditional risk co-variables
Number of subjects: 480
Study 22092534 — intervention group
Group type: EXPERIMENTAL
Intervention: Error-reduced (ER) training program
Number of subjects: 216
Study 22092534 — intervention group
Group type: COMPARATOR
Intervention: Error-strewn (ES) training program
Number of subjects: 216
Study 21298384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based regimens
Number of subjects: 106
Study 21298384 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaliplatin-based regimens
Number of subjects: 106
Study 19695188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold autoblood cardioplegia
Number of subjects: 30
Study 19695188 — intervention group
Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia
Number of subjects: 30
Study 19695188 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 30
Study 16732837 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 1030
Study 16732837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1030
Study 14746870 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS) applied to the motor cortex contralateral to the CRPS-affected side
Number of subjects: 10
Study 14746870 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 10
Study 11335736 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal synchronized intermittent mandatory ventilation (nSIMV) at a rate of 12 bpm with pressure set to achieve at least 12 cm H(2)O and a peak end expiratory pressure of 6 cm H(2)O.
Number of subjects: 54
Study 11335736 — intervention group
Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (nCPAP) at 6 cm H(2)O.
Number of subjects: 54
Study 9243585 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise program
Number of subjects: 46
Study 9243585 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study 8273922 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (F)
Number of subjects: 70
Study 8273922 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (S)
Number of subjects: 70
Study 3717716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitolterol mesylate aerosol
Number of subjects: 29
Study 3717716 — intervention group
Group type: COMPARATOR
Intervention: Isoproterenol hydrochloride aerosol
Number of subjects: 29
Study 29944164 — intervention group
Group type: EXPERIMENTAL
Intervention: High SPF sunscreen applied at 1.3 mg/cm2
Number of subjects: 0
Study 29944164 — intervention group
Group type: EXPERIMENTAL
Intervention: High SPF sunscreen applied at 2.0 mg/cm2
Number of subjects: 0
Study 29944164 — intervention group
Group type: EXPERIMENTAL
Intervention: High SPF sunscreen applied at 0.75 mg/cm2
Number of subjects: 0
Study 29944164 — intervention group
Group type: COMPARATOR
Intervention: Unprotected control skin
Number of subjects: 0
Study 27304988 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration intervention (small vibration devices placed on one hand and one foot, activated in 6 hour ON/OFF sequences for a total of 24 hours)
Number of subjects: 1
Study 27304988 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibration intervention
Number of subjects: 1
Study 24956119 — intervention group
Group type: EXPERIMENTAL
Intervention: MBL-HCV1 treatment
Number of subjects: 11
Study 24956119 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 11
Study 21542734 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% alendronate gel
Number of subjects: 66
Study 21542734 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 66
Study 20064018 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Relaxation (FR)
Number of subjects: 80
Study 20064018 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Medical Care (EMC)
Number of subjects: 80
Study 17578858 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with peripheral vestibular disease
Number of subjects: 110
Study 17578858 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with unilateral canal paresis without balance symptoms
Number of subjects: 110
Study 17578858 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bilateral vestibular loss
Number of subjects: 110
Study 17578858 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 110
Study 15670539 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine plus sildenafil (sildenafil 100 mg 1 hour before sexual intercourse, trimetazidine 20 mg 3 times a day)
Number of subjects: 38
Study 15670539 — intervention group
Group type: COMPARATOR
Intervention: Nitrates (20 mg 3 times a day)
Number of subjects: 38
Study 12075057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fumagillin (60 mg per day orally for two weeks)
Number of subjects: 12
Study 12075057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9861597 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-Plus-Exercise Training (D + EX)
Number of subjects: 22
Study 9861597 — intervention group
Group type: COMPARATOR
Intervention: Diet Alone (D)
Number of subjects: 22
Study 7530801 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine)
Number of subjects: 157
Study 7530801 — intervention group
Group type: EXPERIMENTAL
Intervention: EBVD
Number of subjects: 157
Study 7530801 — intervention group
Group type: COMPARATOR
Intervention: MBVD
Number of subjects: 157
Study 7530801 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVD or EBVD
Number of subjects: 157
Study 7530801 — intervention group
Group type: COMPARATOR
Intervention: ABVD, EBVD, MBVD
Number of subjects: 157
Study 2245418 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training before chemotherapy
Number of subjects: 48
Study 2245418 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 48
Study 2245418 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation training
Number of subjects: 48
Study 2245418 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping style (blunting)
Number of subjects: 48
Study 2245418 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping style (monitoring)
Number of subjects: 48
Study 702130 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine (0.5 mg/kg)
Number of subjects: 0
Study 702130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31985313 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Number of subjects: 0
Study 31985313 — intervention group
Group type: COMPARATOR
Intervention: OnabotulinumtoxinA
Number of subjects: 0
Study 31732149 — intervention group
Group type: EXPERIMENTAL
Intervention: Xhance® 186 μg
Number of subjects: 120
Study 31732149 — intervention group
Group type: EXPERIMENTAL
Intervention: Xhance® 372 μg
Number of subjects: 120
Study 31732149 — intervention group
Group type: COMPARATOR
Intervention: Flonase® 400 μg
Number of subjects: 120
Study 31732149 — intervention group
Group type: COMPARATOR
Intervention: Flovent® HFA 440 μg
Number of subjects: 120
Study 28341685 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised decision aid (DA)
Number of subjects: 12